Recombinant Human IL-28A protein(N-His)(active)
SKU: PKSH034112-100
Recombinant Human IL-28A protein(N-His)(active)
| SKU # | PKSH034112 |
| Expression Host | E.coli |
Description
| Synonyms | IFN-lambda, Cytokine Zcyto, Interferon lambda, Ifnl, ZCYTO, IFN-λ, Cytokine Zcyto20, IFN-lambda-2, IFN-λ2, IL-28A, Interferon lambda-2, Interleukin-28A, IL28A, ZCYTO20, IFNL2, ZCYTO20 |
| Species | Human |
| Expression Host | E.coli |
| Sequence | Pro 27-Val 200 |
| Accession | Q8IZJ0 |
| Calculated Molecular Weight | 20.6 kDa |
| Observed Molecular Weight | 20 kDa |
| Tag | C-His |
| Bio-activity | Measure by its ability to protect HepG2 cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is <20 ng/mL. |
Properties
| Purity | > 98 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 0.1 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS,pH 8.0. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
IL-28A (Interferon-λ2,IFN-λ2), IL-28B/IFN-λ3, and IL-29/IFN-λ1 are type III interferons which are distantly related to IL-10 family and type I IFN family cytokines. Mature human IL-28A is an approximately 22-25 kDa protein that shares 66% amino acid (aa) sequence identity with mouse and rat IL-28A and shows cross-species activity. It shares 96% and 70% aa sequence identity with human IL-28B and IL-29, respectively. IL-28A promotes the Th1 polarization of dendritic cells in the airway and inhibits Th2 and Th17 mediated inflammation. IL-28A additionally exhibits anti-tumor activity, in part by enhancing IL-12 dependent anti-tumor CTL responses in vivo. In contrast, it is up-regulated in invasive bladder cancer where it promotes tumor cell migration.